How LLY (Eli Lilly and Company) Makes Money in 2026: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a pharmaceutical giant like Eli Lilly makes money is essential for investors and anyone interested in the business of biotechnology and drug development. In this post, we break down Eli Lilly's quarterly income statement (Q4 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick Eli Lilly Overview

Eli Lilly operates as a leading global pharmaceutical company, developing and marketing innovative medicines across multiple therapeutic areas. Revenue comes primarily from sales of blockbuster drugs in cardiometabolic health, oncology, immunology, and neuroscience, with key products like Mounjaro and Zepbound driving explosive growth.

Revenue Breakdown

• Total Revenue (Q4 2025): $19.3B (+42.6% YoY)
  • Cardiometabolic Health Revenue: $14.5B (75.1% of total, +59.1% YoY)
  • Oncology Revenue: $2.607B (13.5% of total, +2.2% YoY)
  • Immunology Revenue: $1.541B (8.0% of total, +19.4% YoY)
  • Neuroscience Revenue: $0.46B (2.4% of total, +17.0% YoY)
  • Other: $0.192B
  • Growth is powered by surging demand for GLP-1 agonists like tirzepatide in cardiometabolic health.

Gross Profit and Margins

• Gross Profit: $16.4B (85.1% gross margin)
  • Cost of Revenue: $2.8837B (+20.0% YoY)
  • Eli Lilly maintains robust margins due to its high-value, patent-protected drug portfolio and scalable manufacturing efficiencies.
• Most costs come from manufacturing, raw materials, and distribution for high-volume drugs.

Operating Income and Expenses

• Operating Income: $8.7753B (+70.4% YoY, 45.5% margin)
• Operating Expenses: $7.633B (+27.6% YoY)
  • R&D: $3.802B (+18.4% YoY, 19.7% of revenue) — focused on pipeline expansion in obesity, Alzheimer's, and oncology therapies
  • SG&A: $3.3435B (+37.9% YoY, 17.3% of revenue) — driven by sales force expansion and marketing for new blockbuster launches
  • Eli Lilly continues to prioritize innovation while expanding operations to support global growth.

Net Income

• Pre-Tax Income: $8.265B (+64.0% YoY, 42.8% margin)
• Income Tax: $1.629B (19.7% effective tax rate)
• Net Income: $6.636B (+50.5% YoY, 34.4% net margin)
• Eli Lilly converts a high portion of sales into profit due to pricing power, high-margin drugs, and operational leverage.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives Eli Lilly's Money Machine?

• Cardiometabolic Health: 75.1%+ of revenue / Led by tirzepatide (Mounjaro/Zepbound) with $14.5B in Q4 sales alone
• R&D Investment: $3.802B spend supports a robust pipeline of 70+ molecules in development
• Global Expansion: Investments in manufacturing capacity to meet GLP-1 demand
• Oncology and Immunology: Steady growth areas, though not yet profitable at scale due to competition

Visualizing Eli Lilly's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially R&D and SG&A) taking the largest chunk.
• Even after large investments in R&D, 34.4% of revenue drops to the bottom line.

Key Takeaways

• Eli Lilly's money comes overwhelmingly from Cardiometabolic Health
• High gross and net margins illustrate the power of Eli Lilly's patent-protected blockbuster model
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by GLP-1 drugs and pipeline advancements

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2026)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About Eli Lilly's Income Statement

1. What is the main source of Eli Lilly's revenue in 2025?

Eli Lilly generates over 75% of its revenue from Cardiometabolic Health. Oncology 13.5%, Immunology 8.0%, and Neuroscience 2.4% provide additional diversification.

2. How profitable is Eli Lilly in Q4 2025?

Eli Lilly reported net income of $6.636B in Q4 2025, with a net margin of approximately 34.4%, reflecting strong profitability driven by high-margin drug sales and revenue growth.

3. What are the largest expense categories for Eli Lilly?

The biggest expenses on Eli Lilly's income statement are operating expenses, particularly Research & Development (R&D) and Sales, General & Administrative (SG&A) costs. R&D investment reached $3.802B in Q4 2025, as Eli Lilly prioritizes pipeline development in obesity and neurodegeneration.

4. Why does Other operate at a loss?

Other, despite generating $192M in revenue, contributes modestly to overall profitability. This is because Eli Lilly aggressively invests in early-stage programs, believing these will drive long-term growth—even if the category is unprofitable today.

5. How does Eli Lilly's effective tax rate compare to previous years?

Eli Lilly's effective tax rate in Q4 2025 was 19.7%, consistent with previous years. This moderate rate is primarily due to tax benefits from international operations and R&D credits.